With the help of mRNA technology proven effective during the COVID era, researchers are now closer than ever to creating ...

In pediatric patients aged 6 months to 5 years, the VE of mRNA-1273 against symptomatic infection was modest after a single dose and strong after a second dose.

Phase 3 AURORA trial of Descartes-08 in myasthenia gravis on track to commence in 1H25; Deep and durable responses maintained over 12 months in ...

The mRNA technology behind coronavirus vaccines is now being used to create bespoke vaccines for cancer patients.

The New Normal Five years ago, COVID-19 was declared a global pandemic, marking the official onset of a healthcare crisis ...

Barclays 27th Annual Global Healthcare Conference March 11, 2025 1:30 PM ETCompany ParticipantsRose Loughlin - EVP of ...

Johns Hopkins scientists develop mRNA "booster" as potential new way to treat rare genetic diseases marked by too low levels ...

Daiichi Sankyo is stepping up its interest in RNA therapies, teaming with Nosis Biosciences to design drug candidates capable ...

Automation and artificial intelligence (AI) will be key to a new effort to manufacture millions of RNA vaccines in Africa.

Johns Hopkins Medicine laboratory scientists say they have developed a potential new way to treat a variety of rare genetic ...

Researchers associated with the New York-based Memorial Sloan Kettering Cancer Center have obtained positive results in the ...

Under RFK Jr., HHS has canceled key vaccine meetings. Here's what that means for seasonal flu, bird flu, and childhood ...